Full Press Release Details
Quanterix Enters into a License Agreement
that Grants Abbott Access to Portfolio of Bead-Based Technology Patents for Use in In Vitro Diagnostics
Billerica, Mass. - October 5, 2020 - Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the
science of precision health, today announced it has entered into a non-exclusive royalty-bearing license agreement with
Abbott Laboratories (NYSE: ABT), the global healthcare company. The non-exclusive license grants Abbott access to
Quanterix's portfolio of bead-based technology patents for use in in vitro diagnostic (IVD) applications.
Under the terms of the agreement, Quanterix
will receive an initial license fee, milestone fees subject to the achievement by Abbott of future development, regulatory, and
launch milestones and royalties on the sale of licensed products. To learn more about Quanterix click here
Quanterix is a company that's digitizing
biomarker analysis with the goal of advancing the science of precision health. The company's digital health solution, Simoa,
has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine
the continuum from health to disease. Quanterix' technology is designed to enable much earlier disease detection, better
prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come.
The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology,
cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.
For additional information, please visit https://www.quanterix.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect,"
"plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words
or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking
statements in this news release are based on Quanterix' expectations and assumptions as of the date of this press release.
Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix' actual results
to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix'
filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except
as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
Staci Didner, 407 734 7325
Investor Relations Contact: